WallachBeth Capital Upgrades CTI BioPharma (CTIC) to Buy
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
10 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
WallachBeth Capital upgraded CTI BioPharma (NASDAQ: CTIC) from Hold to Buy with a price target of $4.50.
For an analyst ratings summary and ratings history on CTI BioPharma click here. For more ratings news on CTI BioPharma click here.
Shares of CTI BioPharma closed at $2.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Bernstein SocGen Group Upgrades CapCom Co Ltd. (9697:JP) (CCOEY) to Outperform
- DA Davidson Upgrades Manhattan Associates, Inc. (MANH) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
